Xiidra vs Vuity
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Xiidra | US Vuity | |
|---|---|---|
| Generic name | lifitegrast | pilocarpine ophthalmic |
| Drug class | LFA-1 Antagonist (Eye Drop) | Cholinergic Muscarinic Agonist (Eye Drop) |
| Treats | Dry eye disease | Age-related blurry near vision (presbyopia) |
| Category | Eye Health | Eye Health |
| Manufacturer | Bausch + Lomb | AbbVie (Allergan) |
| Year approved | 2016 | 2021 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $150M | $70M |
| Common side effects | Eye irritation, Unusual taste, Blurred vision, Eye discomfort on application | Headache, Eye redness, Trouble with night vision, Eye pain |
Frequently asked questions
Is Xiidra or Vuity better?
Neither is universally "better." Xiidra (lifitegrast) and Vuity (pilocarpine ophthalmic) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Xiidra and Vuity?
Xiidra is a LFA-1 Antagonist (Eye Drop) made by Bausch + Lomb, while Vuity is a Cholinergic Muscarinic Agonist (Eye Drop) made by AbbVie (Allergan). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Xiidra has the larger estimated TV advertising budget of the two.